BMC Rheumatology · 2022 · 21 citations · 23 references
Life SciencesImmunologyPathologyAutoimmunityImmunopathologyInflammationAutoantibodiesAutoimmune Disease PathogenesisAutoimmune DiseasesAutoimmune PathogenesisMolecular MimicrySystemic Autoimmune DiseaseAutoimmune-associated Interstitial Lung DiseaseDermatomyositis Skin DiseaseImmune Tolerance BreakingInfection-induced AutoimmunityInfection-triggered AutoimmunityMelanoma Differentiation-associated Protein 5Pathogenic AutoantibodiesSars-cov-2 Infection
BACKGROUND: Autoimmune disease following COVID-19 has been studied intensely since the beginning of the pandemic. Growing evidence indicates that SARS-CoV-2 infection, by virtue of molecular mimicry can lead to an antigen-mediated cross-reaction promoting the development of a plethora of autoimmune spectrum diseases involving lungs and extrapulmonary tissues alike. In both COVID-19 and autoimmune disease, the immune self-tolerance breaks, leading to an overreaction of the immune system with production of a variety of autoantibodies, sharing similarities in clinical manifestation, laboratory, imaging, and pathology findings. Anti-Melanoma Differentiation-Associated gene 5 dermatomyositis (anti-MDA5 DM) comprises a rare subtype of systemic inflammatory myopathies associated with characteristic cutaneous features and life-threatening rapidly progressive interstitial lung disease (RP-ILD). The production of anti-MDA5 autoantibodies was proposed to be triggered by viral infections. CASE PRESENTATION: A 20-year-old male patient with polyarthritis, fatigue and exertional dyspnea was referred to our department. An elevated anti-MDA5 autoantibody titer, myositis on MRI, ground glass opacifications on lung CT and histological features of Wong-type dermatomyositis were confirmed, suggesting the diagnosis of an anti-MDA5 DM. Amid further diagnostic procedures, a serologic proof of a recent SARS-CoV-2 infection emerged. Subsequently, the patient deteriorated into a fulminant respiratory failure and an urgent lung transplantation was performed, leading to remission ever since (i.e. 12 months as of now). CONCLUSIONS: We report a unique case of a patient with a new-onset anti-MDA5 DM with fulminant ARDS emerging in a post-infectious stage of COVID-19, who underwent a successful lung transplantation and achieved remission. Given the high mortality of anti-MDA5 DM associated RP-ILD, we would like to highlight that the timely recognition of this condition and urgent therapy initiation are of utmost importance.
23
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Hiroki Kato, Osamu Takeuchi, Shintaro Sato et al. · Nature · 2006 · 3.8K citations
New-onset IgG autoantibodies in hospitalized patients with COVID-19
Sarah E. Chang, Allan Feng, Wenzhao Meng et al. · Nature Communications · 2021 · 469 citations · Full text
MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells
Xin Yin, Laura Riva, Yuan Pu et al. · Cell Reports · 2021 · 414 citations · Full text
Spyridon Deftereos, Dimitrios A. Vrachatis, Gerasimos Siasos et al. · JAMA Network Open · 2020 · 399 citations · Full text